No Correlation Between Interleukin-10 Gene Promoter Polymorphisms and Hepatitis B Virus Infection Outcome

Masooomeh Sofian \(^1\), Ebrahim Kalantar \(^2\), Arezoo Aghakhani \(^3\), Soudabeh Hosseini \(^2\), Mohammad Banifazl \(^4\), Ali Eslamifar \(^3\), Ali Jourabchi \(^5\), Ali Asghar Farazi \(^1\), Amitis Ramezani \(^3,\)*

\(^1\) Tuberculosis and Pediatric Infectious Research Center, Arak University of Medical Sciences, Arak, IR Iran
\(^2\) Gholhak Laboratory, Tehran, IR Iran
\(^3\) Department of Clinical Research, Pasteur Institute of Iran, Tehran, IR Iran
\(^4\) Iranian Society for Support Patients With Infectious Disease, Tehran, IR Iran
\(^5\) Department of Infectious Disease, Arak University of Medical Sciences, Arak, IR Iran

\*Corresponding author: Amitis Ramezani, Department of Clinical Research, Pasteur Institute of Iran, 13164, Pasteur Ave., Tehran, IR Iran. Tel: +98-2166968852, Fax: +98-2166465332, E-mail: amitisramezani@hotmail.com.

ABSTRACT

Background: Single nucleotide polymorphisms (SNP) in the promoter region of the interleukin (IL)-10 genes have a role in determining hepatitis B virus (HBV) outcome.

Objectives: This study evaluates the correlation between HBV infection and SNP in IL-10 gene promoter.

Patients and Methods: Ninety-six HBV-infected patients (32 chronic hepatitis B infection patients, 34 healthy carriers, 30 spontaneously recovered cases) and 31 healthy controls were enrolled. Three biallelic (-819,-592,-1082) regions in the IL-10 gene promoter were sequenced for all patients.

Results: Genotypes and haplotypes of IL-10 gene promoter region at position -1082, -819 and -592 were not significantly different among controls, HBV recovered cases, carriers and chronic HBV patients. Nevertheless, A/A genotype at position -592 and T/T genotype at position -819 were more frequently seen in the HBV clearance group, while frequency of G/G genotype at position -1082 was more prevalent in the persistence group. GCC/GCC and GCC/ACC haplotypes were significantly observed in anti-HBe positive individuals.

Conclusions: Our findings showed that IL-10 promoter polymorphisms were not correlated with HBV infection prognosis. Nevertheless, individuals carrying high and intermediate producer of IL-10 haplotypes had a better ability to develop anti-HBe than low producer carriers.

Keywords: Hepatitis B virus; Genotype; Interleukin-10; Haplotypes

Copyright © 2013, Kowsar Corp.; Published by Kowsar Corp.
1. Background

The mechanisms of susceptibility to chronic hepatitis B virus (HBV) infection are not well clarified (1-3). Host genetic and viral factors are strong components in determining the outcomes of HBV infection (1). There is some evidence that the capacity for cytokine production in individuals may predict the progression of HBV infection (4-6). Interleukin (IL)-10 is an important anti-inflammatory cytokine secreted by several cells including T regulatory lymphocytes, activated macrophages and T helper (Th) 2 cells. The levels of IL-10 production determine immune regulation and the balance between the cellular and humoral responses (7). Several polymorphisms within the IL-10 gene promoter region have been described, including positions -1082, -819, and -592 (8). The -1082 G/G genotype is associated with high IL-10 production, but the -1082 G/A and A/A are correlated with intermediate and low production, respectively. Polymorphisms at position -819 and -592 have no independent influence on IL-10 production (9). The T and C alleles at position -819 of IL-10 promoter gene were totally in linkage disequilibrium with the IL-10-592 A and C alleles, respectively. The A allele at position-592 was solely relevant to the -1082 A allele. These make three different haplotypes: GCC, ACC and ATA (10).

2. Objectives

There are contradictory reports about the exact effects of IL-10 promoter gene polymorphisms on the natural outcome of HBV infection (11-14). The present study was undertaken in a central Iranian city and aimed to evaluate the correlation between HBV infection and single nucleotide polymorphisms (SNP) in the promoter regions of the IL-10 gene.

3. Patients and Methods

3.1. Study Population

96 HBV infected patients (58 males, 38 females) who were admitted to a hepatitis referral center in a city located in central Iran (Arak), and 31 matched healthy controls from a blood transfusion organization were enrolled consecutively in this study, from May 2011 to July 2011. They included 32 chronic hepatitis B patients (CHB), 34 healthy carriers, and 30 recovered cases. HBV recovery was defined as patients with negative hepatitis B surface antigen (HBsAg), positive hepatitis B core antibody (anti-HBc), and positive hepatitis B surface antibody (anti-HBs). The healthy carrier group was defined as individuals with a positive HBsAg for more than six months and elevated aminotransferases \[ \geq 2 \text{ times the upper limit of normal } \langle 35 \text{IU/L} \]. The healthy carriers and CHB groups were merged together and considered as the persistent group in this study. All of the cases were negative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis D virus (HDV) as measured by ELISA. This project was approved by the Arak University of Medical Sciences ethics committee and signed informed consent was gathered from all patients before study initiation.

3.2. Serological Testing

Hepatitis B surface antigen (HBsAg), antibodies to HBsAg (anti-HBs) and hepatitis B core antigen (anti-HBc) were tested by enzyme-linked immunosorbent assay (ELISA) using a commercial kit (Hepanostika, bioMerieux, Boxtel, Netherlands). All Samples were also checked for hepatitis B e antibody (anti-HBe), hepatitis B e antigen (HBeAg) and hepatitis C antibody (anti-HCV) using ELISA. The commercial kits used were as follows: anti-HCV (Bio-Rad Laboratories, Segrate, Italy) and HBeAg and anti-HBe (Radim, Barcelona, Spain). Anti-HCV reactivity was confirmed by recombinant immunoblot assay (RIBA Innomogenetics, Gent, Belgium). All samples were tested for anti-HDV antibodies by the ELISA kit (Dia.Pro Diagnostic Bioprobessri, Milano, Italy). HIV-antibody status was assessed by ELISA (MP Biomedicals, Illkirch, France) and positive tests were confirmed by the Western blot assay (Diaplus, San Francisco, USA).

3.3. IL-10 Genotyping

Genomic DNA was extracted from 300μl of whole blood from each patient using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The three biallelic IL-10 promoter polymorphisms were detected by PCR using primers that amplified a short fragment of DNA containing the polymorphisms sites in combination with direct sequencing. The sequence of primers used in the PCR provided by Metabion international AG ( Martinsried, Germany) was as follows:

- IL10 −819 F: 5′-ATAGGAGGTCCTCCTCTTCTC-3′
- IL10 −819 R: 5′-ATAGGAGGTCCTCCTCTTCTC-3′
- IL10 −592 F: 5′-AAATCGGGGTAAAGGAGC-3′
- IL10 −592 R: 5′-AGCAGCCCTTCCATTTTACT-3′

We then electrophoresed the PCR products and visualized them on a gel documentation system. The final PCR products were purified [High Pure PCR product purification kit (Roche Diagnostics GmbH, Mannheim, Germany)] and sequenced by the ABI sequencer.

3.4. Statistical Analysis

Statistical tests were used including the Chi-square and Fisher’s exact test along with the SPSS 16.0 data analysis software package; \( P < 0.05 \) were considered as statistically significant. The odds ratio (OR) and the 95% confidence interval (95 % CI) were calculated. Logistic regression analysis was also used to determine the correlation of a specific genotype and/or haplotype with HBV infection outcome.
4. Results

4.1. IL-10 Promoter Polymorphisms in HBV Infected Patients and Healthy Controls

IL-10 gene promoter genotype and haplotype at position -1082, -819 and -592 were checked for the HBV infected patients, recovered HBV cases and healthy controls. There was no significant difference between these groups regarding IL-10 gene promoter genotype and haplotype distribution (Table 1).

4.2. Comparison of IL-10 Gene Promoter Polymorphisms Between Persistent and Recovered Groups

IL-10-1082 G/G and G/A frequency were slightly higher in the persistent HBV infection group while the -1082 A/A was more frequent in the recovered group. However, the IL-10-1082 polymorphisms did not differ significantly between persistent and recovered groups (Table 2). The frequency of C/C genotype at position -592 of IL-10 gene promoter was slightly different in the persistence group than that in the HBV clearance group (45.5% vs. 36.7%); but

A/A genotype at position -592 of IL-10 gene promoter was slightly higher in cases with clearance of HBV infection. 64.4% of the persistence group had C alleles in comparison with 58.3% of the recovered group. A alleles were seen in 32.6% of patients with persistent HBV infection but the frequency of this allele was 41.7% in recovered cases.

We found slightly different frequency of IL-10-819 T/T in the recovered group and -819 C/C in the persistent HBV

---

Table 1. Association Between IL-10 Gene Promoter Polymorphism in Different Study Groups

| Genotype | Chronic HBV Infected Group, No. (%) (n = 32) | HBV Carrier Group, No. (%) (n = 34) | Recovered Group, No. (%) (n = 30) | Healthy Control Group, No. (%) (n = 31) | P value |
|----------|-----------------------------------------------|-------------------------------------|-----------------------------------|----------------------------------------|---------|
| Locus, -592 | | | | | |
| A/A | 2 (6.2) | 5 (14.7) | 6 (20) | 4 (12.9) | NSa |
| C/A | 15 (46.9) | 14 (41.2) | 13 (43.3) | 11 (35.5) | NS |
| C/C | 15 (46.9) | 5 (44.1) | 11 (36.7) | 16 (51.6) | NS |
| Locus, -819 | | | | | |
| C/C | 15 (46.9) | 15 (44.1) | 11 (36.7) | 16 (51.6) | NS |
| C/T | 15 (46.9) | 14 (41.2) | 13 (43.3) | 11 (35.5) | NS |
| T/T | 2 (6.2) | 5 (14.7) | 6 (20) | 4 (12.9) | NS |
| Locus, -1082 | | | | | |
| A/A | 14 (43.8) | 18 (52.9) | 17 (56.7) | 13 (41.9) | NS |
| G/A | 15 (46.9) | 12 (35.3) | 12 (40) | 15 (48.4) | NS |
| G/G | 3 (9.4) | 4 (11.8) | 1 (3.3) | 3 (9.7) | NS |

a Abbreviations: NS, not significant

Table 2. Association Between IL-10 Gene Promoter Polymorphism and HBV Persistence

| Genotype | Persistent Infection Group, No. (%) (n = 66) | Recovered Group, No. (%) (n = 30) | P valuea | ORb | 95% CI (OR) |
|----------|-----------------------------------------------|-----------------------------------|-----------|------|-------------|
| Locus, -592 | | | | | |
| A/A | 7 (10.6) | 6 (20) | 0.219 | 0.475 | 0.144-1.559 |
| C/A | 29 (43.9) | 13 (43.1) | 0.956 | 1.025 | 0.429-2.448 |
| C/C | 30 (45.5) | 11 (36.7) | 0.421 | 1.439 | 0.593-3.493 |
| Locus, -819 | | | | | |
| C/C | 30 (45.5) | 11 (36.7) | 0.421 | 1.439 | 0.593-3.493 |
| C/T | 29 (43.9) | 13 (43.3) | 0.956 | 1.025 | 0.429-2.448 |
| T/T | 7 (10.6) | 6 (20) | 0.219 | 0.475 | 0.144-1.559 |
| Locus, -1082 | | | | | |
| A/A | 32 (48.5) | 17 (56.7) | 0.458 | 0.720 | 0.302-1.716 |
| G/A | 27 (40.9) | 12 (40) | 0.933 | 1.038 | 0.431-2.504 |
| G/G | 7 (10.6) | 1 (3.3) | 0.258 | 3.441 | 0.404-29.3 |

a P value < 0.05 was statistically significant
b Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval
Table 3. Haplotype Analysis of IL-10 Gene Promoter in Persistent and Recovered Groups

| Haplotype | Persistent Infection Group, No. (%) | Recovered Group, No. (%) | P value<sup>a</sup> | OR<sup>b</sup> | 95% CI<sup>b</sup> (OR) |
|-----------|-------------------------------------|--------------------------|----------------------|------------------|-------------------------|
| **Homozygous Type** | | | | | |
| ACC/ACC   | 8 (12.1) | 3 (10) | 1 | 1.241 | 0.305-5.051 |
| GCC/GCC   | 7 (10.6) | 1 (3.3) | 0.428 | 3.441 | 0.404-29.3 |
| ATA/ATA   | 7 (10.6) | 6 (20) | 0.218 | 0.475 | 0.144-1.559 |
| **Heterozygous Type** | | | | | |
| GCC/ACC   | 15 (22.7) | 7 (23.3) | 1 | 0.966 | 0.347-2.689 |
| GCC/ATA   | 12 (18.2) | 5 (16.7) | 1 | 1.111 | 0.353-3.495 |
| ACC/ATA   | 17 (25.8) | 8 (26.7) | 1 | 0.954 | 0.358-2.540 |

<sup>a</sup> P value < 0.05 was statistically significant
<sup>b</sup> Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval

4.3. Correlation between HBeAg Seroconversion and IL-10 Genotype and Haplotype

No significant difference was observed between the HBeAg and anti-HBe positive groups in the genotyping analysis (Table 4). Nevertheless, in the haplotype analysis, the GCC/GCC homozygous type was found more frequently in HBV clearance group. However, these differences were not significant between these groups (Table 3).
Gene Polymorphisms and HBV Infection

Sofian M et al.

In the present study we examined the polymorphisms of promoter regions of IL-10 gene and the correlation of these polymorphisms with HBV clearance and disease progression. The frequency of A/A genotype at position -592 and T/T genotype at position -819 of IL-10 gene promoter were higher in the HBV clearance group than that in the persistence group. The G/G genotype at position -1082 was more prevalent in the persistence group. Individuals carrying high and intermediate producer haplotypes of IL-10 had more capacity to develop anti-HBe than low producer haplotypes. Cytokines play a critical role in modulating inflammatory and immune responses. Polymorphisms in the regulatory regions of the cytokine genes have important impact on their expression. Thus the cytokine genes polymorphisms have a major contribution in predicting disease susceptibility and clinical outcome (3). IL-10 is a crucial cytokine with immune-regulatory and anti-inflammatory effects and is associated with many diseases (15). IL-10 is produced by Th2 cells, T regulatory lymphocytes and activated macrophages and inhibits expression of other pro-inflammatory cytokines such as IFN-gamma, IL-2 and TNF-alpha in Th1 cells (16). IL-10 gene polymorphisms can affect the transcription, translation and secretion of IL-10 (15). Polymorphisms in the IL-10 promoter region and associations with HBV infection and progression have been examined widely in different populations throughout the world (7, 11-14, 17). There are three classic haplotypes in the IL-10 promoter region including GCC, ACC, and ATA (9). The GCC haplotype produces high, ACC medium, and ATA low levels of IL-10 (18, 19). The three proximal promoter SNPs and haplotypes have been associated with hepatitis B infection outcomes in Korean (11, 12), Chinese (20-22), Japanese (23) and African American populations (9, 24). These reports suggest the important role of IL-10 variation in HBV infection outcome. Cheong et al. (11) reported that high producer genotypes of IL-10 (IL-10-592 C/C) carriers had a better capacity to recover from HBV spontaneously versus individuals with low IL-10 producer allele (IL-10-592A). In contrast, Shin et al. (12) indicated that patients who have IL-10 h2 (high IL-10 producers) show an accelerated course of chronic HBV infection. Turner et al. (19) also reported that people with the IL-10-592 A/A genotype had lower IL-10 levels and a favorable HBV disease outcome. Miyazoe et al (5) has also found that carriers of the A/A haplotype (low IL-10 production ability) have favorable HBV-related outcomes. In another study in Iran, IL-10-592 C/C was significantly more common in patients with occult HBV infection (25). In an investigation by Peng et al. (20), patients with IL-10 intermediate producer genotypes were more likely to produce anti-HBe than IL-10 low producer genotype carriers, so HBeAg seroconversions were more frequently seen in IL-10 intermediate producer genotypes or haplotypes. In another study by Wu et al (13) the IL-10-1082 G/G genotype polymorphism was associated with earlier HBeAg seroconversion and lower HBV viral load compared to A allele carriers. Gao et al (7) showed that IL-10-1082 AA/AG did not differ significantly between subjects with HBV infection and controls. They also reported that the IL-10-1082 A/G alleles and IL-10-592 A/C polymorphisms did not differ significantly between cases and controls. A meta analysis conducted by Lu et al (15) indicated that the G and A alleles in IL-10-1082 were not associated with HBV infection in the Asian population. The study by Zhang et al. (14) showed no significant difference at position -1082G/A, -819T/C and -592A/C of IL-10 gene promoter region among normal controls, recovered HBV individuals and chronic HBV patients. Nevertheless, it was reported that T/T genotype at position -819T/C and A/A genotype at position -592A/C were significantly more frequent in chronic hepatitis B patients than in asymptomatic HBV carriers. Our results showed no significant difference in frequencies of genotypes and haplotypes of IL-10 gene promoter region at position -1082, -819 and -592 among cases with HBV infection and controls, which is in agreement with findings of Zhang et al (14). The results of the Gao et al (7), and Lu et al (15) studies are in contrary with Miyazoe et al (5), Shin et al (12), Turner (9) and Cheong et al (11) investigations. These conflicting results may be due to the influence of other genes on HBV progression than just a direct link between IL-10 expression and HBV outcome. Moreover they can be related to epidemiological and geographical factors and study circumstances such as the characteristics and number of the patients and HBV genotype variations. Our study also showed that patients with high and intermediate producer haplotypes of IL-10 had more ability to produce anti-HBe than low producer haplotype carriers and this is in agreement with Peng et al (20) and Wu et al (13) results. These findings are in concordance with the inhibiting effects of IL-10 on pre-inflammatory cytokines and self-limiting HBV infection in high producer genotype carriers. In conclusion, our study showed that IL-10 promoter region polymorphisms may not be correlated with HBV infection prognosis. Nevertheless, individuals carrying high and intermediate producers of IL-10 haplotypes had more ability to develop anti-HBe than low producer carriers. However, due to the limited number of patients in the current study, a conclusion cannot be reached regarding the correlation of IL-10 gene promoter polymorphisms and HBV infection outcome, so further studies should be carried out to determine this association.

Acknowledgments

The authors are grateful to Arak University of Medical Sciences for financial support of this study.
Authors’ Contribution

Amitis Ramezani contributed in preparation the manuscript. Ali Jourabchi and Ali Asghar Farazi collected the clinical samples. Ebrahim Kalantar and Soudabeh Hosseini performed laboratory tests. Mohammad Banifazl is the guarantor of integrity of the entire study. Arezoo Aghakhani and Ali Eslamifar collected and analyzed the data and revised the manuscript. Masoomeh Sofian contributed in conception and design of the study, collecting the clinical samples.

Financial Disclosure

Authors declare there is no financial disclosure.

Funding/Support

This study was supported by Arak University of Medical Sciences.

References

1. Ramezani A, Hasanjani Roshan MR, Kalantar E, Eslamifar A, Banifazl M, Taeb J, et al. Association of human leukocyte antigen polymorphism with outcomes of hepatitis B virus infection. J Gastroenterol Hepatol. 2008;23(1):276-281
2. Ramezani A, Aghakhani A, Kalantar E, Banifazl M, Eslamifar A, Velayati AA. HLA “A301”and “A301” predispose patients to persistent hepatitis B infection. J Gastrointestin Liver Dis. 2009;18(3):217-224
3. Yang G, Liu J, Han S, Xie H, Du R, Yan Y, et al. Association between hepatitis B virus infection and HLA-DQB1 genotyping in Shaanxi Han patients in northwestern China. Tissue Antigens. 2007;69(2):170-5
4. Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Annu Rev Immunol. 2001;19:65-90
5. Miyazoe S, Hamasaki K, Nakao K, Nakao K, et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol. 2002;97(8):2066-92
6. Mosman TR, Frank JD. Properties and Functions of Interleukin-10. In: Mosman TR, editor. Advances in Immunology. Academic Press; 1994. p.1-26
7. Gao QJ, Liu DW, Zhang SY, Jia M, Wang LM, Wu LH, et al. Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. World J Gastroenterol. 2009;15(44):5600-9
8. Wang S, Huang D, Sun S, Ma W, Zhen Q. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa. Virology. 2011;413:28
9. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson RV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24(1):8
10. Eskdale J, Keijzers V, Huizinga T, Gallagher G. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun. 1999;2(2):15-5
11. Cheong JY, Cho SW, Hwang IL, Yoon SK, Lee JH, Park CS, et al. Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms. J Gastroenterol Hepatol. 2006;21(7):1163-9
12. Shin HS, Park BI, Kim LH, Jung JH, Kim JY, Yoon HI, et al. Interleukin-10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet. 2003;12(4):901-6
13. Wu JF, Ni YH, Lin YT, Lee TJ, Hsu SH, Chen HL, et al. Human interleukin-10 genotypes are associated with different precore/core gene mutation patterns in children with chronic hepatitis B virus infection. J Pediatr. 2011;158(3):808-13
14. Zhang PA, Li Y, Yang XS. [Associated study on interleukin 10 gene promoter polymorphisms related to hepatitis B virus infection in Chinese Han population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006;35(4):410-4
15. Lu YL, Wu X, Huang HL, Dai LC. Allele polymorphisms of interleukin-10 and hepatitis B, C virus infection. Chin Med J (Engl). 2010;133(13):1844-1847
16. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004;22:929-79
17. Truelove AL, Oleksyk TK, Shrestha S, Thio CL, Goedert JJ, Donfield SM, et al. Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome. Int J Immunogenet. 2008;35(3):259-64
18. Crawley E, Kay R, Silibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 1999;42(6):1300-8
19. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology. 1999;30(2):526-30
20. Peng XM, Huang YS, Ma HH, Gu L, Xie QF, Gao ZL. Interleukin-10 promoter polymorphisms are associated with the mode and sequel of HBeAg seroconversion in patients with chronic hepatitis B virus infection. Liver Int. 2006;26(3):326-33
21. Zhang TC, Pan FM, Zhang LZ, Gao YF, Zhang ZH, Gao J, et al. Meta-analysis of the relation of polymorphism at sites -1082 and -592 of the IL-10 gene promoter with susceptibility and clearance to persistent hepatitis B virus infection in the Chinese population. Infection. 2011;39(3):217
22. Zhu QR, Ge YL, Gu SQ, Yu H, Wang JS, Gu XH, et al. Relationship between cytokines gene polymorphism and susceptibility to hepatitis B virus intrauterine infection. Chin Med J (Engl). 2008;131(9):1604-9
23. Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection—association between TGF-beta polymorphisms and hepatocellular carcinoma. J Hepatol. 2005;42(4):505-10
24. Eskdale J, Gallagher G, Verweij CL, Keijzers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A. 1998;95(6):3945-50
25. Ahmadabadi BN, Hassanshahi G, Arababadi MK, Leanza C, Kennedy D. The IL-10 promoter polymorphism at position -592 is correlated with susceptibility to occult HBV infection. Inflammation. 2012;35(3):310-21